Xie et al. recently discovered that in pancreatic ductal adenocarcinoma (PDAC), targeted deletion of PTK2B impairs the differentiation and polarization of monocyte-derived macrophages, remodels the PDAC microenvironment, and enhances the efficacy of anti-PD-1 immunotherapy [47]. The gene discussed is PTK2B; the disease is pancreatic ductal adenocarcinoma.